copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Nirmatrelvir and the Risk of Post–COVID-19 Condition - JAMA Network Absolute risk reduction of nirmatrelvir compared with the control group per 100 persons at 180 days and associated 95% CIs were estimated based on the difference of survival probability in the nirmatrelvir group compared with the control group
Yan Xie, Taeyoung Choi, Xie, Y , Choi, T , Al-Aly, Z (2023) Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition JAMA Internal Medicine, 183 (6), 554-564 https: doi org 10 1001 jamainternmed 2023 0743
JAMA Internal Medicine Recent studies among US veterans (mostly male) suggest that nirmatrelvir and molnupiravir reduce the risk of some sequelae of COVID-19 We performed a cohort study of the 2 drugs in PCC in older patients who were Medicare enrollees
While Waiting for a Randomized Clinical Trial of . . . - JAMA Network But does it prevent PCC? The right study to answer this question would be a randomized clinical trial with a prespecified definition of PCC While we wait for this study, we thought that the data from the cohort study in this issue of JAMA Internal Medicine from Xie and colleagues 2 was informative
While Waiting for a Randomized Clinical Trial of Nirmatrelvir . . . - PubMed Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition Xie Y, Choi T, Al-Aly Z Xie Y, et al JAMA Intern Med 2023 Jun 1;183 (6):554-564 doi: 10 1001 jamainternmed 2023 0743 JAMA Intern Med 2023 PMID: 36951829 Free PMC article
June 1, 2023 Issue of JAMA Internal Medicine | JAMA Network What Should I Know About Hormones for Symptoms of Menopause? This JAMA Internal Medicine Patient Page describes hormone therapy to treat the symptoms of menopause Read the June 1, 2023 issue Volume 183, Number 6
JAMA Internal Medicine —The Year in Review, 2023 Our year-end statistics reflect the broad global effect and reach of JAMA Internal Medicine Despite the anticipated decrease in COVID-19 articles and the associated deflation in the Journal Impact Factor, the journal performance has remained robust
Risk Factors Associated With Post-COVID-19 Condition: A Systematic . . . Conclusions and relevance: This systematic review and meta-analysis demonstrated that certain demographic characteristics (eg, age and sex), comorbidities, and severe COVID-19 were associated with an increased risk of PCC, whereas vaccination had a protective role against developing PCC sequelae